Biotech Values

[DewDiligence]

...I see ENTA a great value here since Abbvie seems totally committed and there is very little chance they won't be approved.

Many biotech investors don’t seem to realize that phase-3 trials for antiviral drugs are much less risky than phase-3 trials for other kinds of drugs. Efficacy at impeding viral replication can be well-established in phase-2, and the standard efficacy endpoint for HCV regimens (SVR12) is a lab measurement with no placebo effect. Thus, most phase-3 HCV trials are essentially safety/tolerability trials.